UK markets closed

Shattuck Labs, Inc. (STTK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.65+0.92 (+10.54%)
At close: 04:00PM EST
9.60 -0.05 (-0.52%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close8.73
Open9.17
Bid9.65 x 1400
Ask9.99 x 900
Day's range9.04 - 10.31
52-week range1.33 - 10.66
Volume644,069
Avg. volume1,792,418
Market cap454.868M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

    - Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients; initial data build on the dose-escalation data featured in a poster presentation at the American Society of Hematology (ASH) Annual Meeting – - Completed initial enrollment in Phase 1B dose-expansion cohorts for frontline HR-MDS and TP53m

  • GlobeNewswire

    Shattuck Labs Announces Participation in Upcoming March Conferences

    AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024. Presentation DetailsConference: TD Cowen 44th Annual Health Care ConferenceFormat: Pan

  • PR Newswire

    Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

    Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber; "Shattuck") to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases.